Todd Bertoch, MD

Articles by Todd Bertoch, MD

Where Will the New Nonopioid Journavx Fit Best Along the Acute Pain Management Continuum? Phase 3 Investigator Shares Thinking

Where Will the New Nonopioiod Suzetrigine (Journavx) Fit Best Along the Acute Pain Management Continuum? Phase 3 Investigator Shares Thoughts

February 3rd 2025

Suzetrigine (Journavx) PI Todd Bertoch, MD, identifies the sweet spot where he thinks the new NaV1.8 inhibitor will be most effective in post-surgical and other moderate-to-severe acute pain.

Suzetrigine approval: lead investigator highlights pivotal phase 3 clinical trial results

Journavx Approval: Lead Investigator Highlights Pivotal Phase 3 Clinical Trials

ByTodd Bertoch, MD,Grace Halsey

January 30th 2025

Todd Bertoch, MD, reviews the significant findings on relief of pain from the 2 pivotal studies and lauds the remarkable safety profile of the novel nonopoid analgesic Journavx.

Todd Bertoch, MD

Articles by Todd Bertoch, MD

Where Will the New Nonopioiod Suzetrigine (Journavx) Fit Best Along the Acute Pain Management Continuum? Phase 3 Investigator Shares Thoughts

Journavx Approval: Lead Investigator Highlights Pivotal Phase 3 Clinical Trials

Latest Updated Articles

Trending on Patient Care Online

Oral Semaglutide Wins Approval to Reduce Risk of MACE in Adults with T2D at High Risk

Grail Reports Strong Performance for Galleri Blood Test Ahead of FDA Submission

Most Parents Support Childhood Vaccines, But Doubt Flu and COVID-19 Shots: Daily Dose

FDA Approves TSLP Inhibitor Tezepelumab for Chronic Rhinosinusitis With Nasal Polyps